Create
Learn
Share

HIV Drugs

rename
ekadar's version from 2017-01-07 19:20

Genetics

Question Answer
3 structural genesenv (envelope gp41,gp120), gag (capsid), pol (RT polymerase)
envgp41 (fusion and entry)
gp120 (attachment to host T Cell)
gagp24 (capsid protein) (24 yos hate gagging)
polreverse transcriptase
gp120attachment to host CD4 t cell (antibodies to this can cross placenta)
gp41fusion and entry
p24capsid (gag)
p17matrix (shell) (i was 17 when i saw the matrix)
HIV binds what 2 coreceptorsCD4 as well as CXCR4 or CCR5
HIV binds what target cellCD4+ T cells
Mutation resulting in slower courseheterzygous CCR5 mutation
Mutation resulting in immunityhomozygous CCR5 mutation
memorize

HIV therapy

Question Answer
"navir"s mechinhibits HIV-1 protease (pol gene) → prevent cleaving of HIV mRNA into their functional parts
"navir"s toxHyperglycemia
GI intolerance (nausea/diarrhea)
Lipodystrophy
Ritonavir toxinhibits P450
Indinavir toxNephropathy
Hematuria
NRTIs mechNucleoside analogs → activated via phosphorylation → competitively inhibit nucleotide binding to reverse transcriptase → terminate DNA chain d/t lack of 3' OH group
must be phosphorylated to be active (except tenofovir, a nucleoTide)
NRTIs toxBM suppression - can be reversed w G-CSF and erythropoietin
peripheral neuropathy
lactic acidosis (nucleosides)
rash (non-nucleosides)
Zidovudane (AZT) clinical useNRTI used for general prophylaxis during pregnancy to reduce risk of fetal transmission
Tenovirnucleotide analog (NRTI) so it does not have to be activated
NNRTIs mechbind to reverse transcriptase at different site than NRTIs
Don't require phosphorylation to be active or compete with nucleotides
NNRTIs toxBM suppression - can be reversed w G-CSF and erythropoietin
peripheral neuropathy
lactic acidosis (nucleosides)
rash (non-nucleosides)
RaltegravirIntegrase inhibitor → inhibits HIV genome integration into host cell chromosome. Prevents synthesis HIV mRNA
Raltegravir toxrash, myopathy
Interferons mechglycoproteins synthesized by virus-infected cells
block replication of both RNA and DNA viruses
IFN-α clinical usechronic hep B and C
Kaposi's sarcoma
IFN-β clinical useMS
IFN-γ clinical useNADPH oxidase deficiency (CGD)
Interferons toxneutropenia
myopathy
enfuviritidebinds gp41 inhibiting viral entry. Skin reactions at the injection site are commonly seen
maravirocbinds CCR-5 on t cells blocking HIV gp120 attachment and preventing viral cell entry
HIV therapy regimen2NRTIS and 1 NNRTI or protease inhibitor or integrase inhibitor
memorize

Name HIV Drug

Question Answer
delaviridineNNRTI
efavirenzNNRTI
nevirapineNNRTI
raltegravirintegrase inhibitor
enfuvirtidebinds gp41
maravirocbinds CCr5
TenofovirNRTI
EmtricitabineNRTI
AbacavirNRTI
LamivudineNRTI
ZidovudineNRTI
DidanosineNRTI
StavudineNRTI
NevirapineNNRTI
EfavirenzNNRTI
DelavirdineNNRTI
Raltegravirintegrase inhibitor
memorize